Pharma BD Deal Intelligence
Valeant comes out a winner after upping its Salix bid to $173 per share, beating rival bidder Endo International in the takeover battle for the…
Valeant acquired Salix for $15.8B.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Valeant acquired Salix for $15.8B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals / Salix Pharmaceuticals (this deal) | 2015 | $15.8B | 39 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2015 deals · Gastroenterology deals